An audio webcast link for the event, when available, will be posted to Bionomics’ website in the Investors-Events and Presentations section.
FOR FURTHER INFORMATION PLEASE CONTACT:
Investor Relations Mr. Vice President, Strategy and Corporate Development +1 (650) 524-5143 cbernstein@bionomics.com.au | Investor Relations kgardner@lifesciadvisors.com |
About
Bionomics (ASX:BNO, NASDAQ:BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious CNS disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside
www.bionomics.com.au
Source:
2022 GlobeNewswire, Inc., source